Work

Recombinant alpha-2B interferon treatment for childhood t-lymphoblastic disease in relapse. A pediatric oncology group phase II study

Year: 1994

Type: article

Abstract: BACKGROUND: Children with chemotherapy refractory T-cell lymphoblastic leukemia/lymphoma were given alpha-interferon (alpha-IFN) to evaluate the efficacy and toxicity of this biologic response modifier. METHODS: Twenty children with T-cell acute lymphoblastic leukemia (T-cell ALL) in marrow relapse and one patient with mediastinal recurrence of T-cell non-Hodgkin's lymphoma (T-cell NHL) were enrolled. All patients had failed at least two previous multiagent drug trials. Recombinant alpha-IFN was given at 30 million U/M2/dose intravenously or subcutaneously for 10 doses over 14 days, followed by 3 doses per week until disease progression occurred. RESULTS: One child had a complete response (< 5% blasts) and three patients a partial response (5-25% blasts) in their bone marrow. All patients eventually showed signs of progressive disease. Significant toxicities included cardiac hypofunction in two patients and profound lethargy in two patients. CONCLUSIONS: alpha-IFN is tolerated in children with T-cell ALL and T-cell NHL and has activity against chemotherapy resistant disease.

Source: Cancer

DOI: 10.1002/1097-0142(19940701)74:1<197::aid-cncr2820740131>3.0.co;2-9

Authors: Stephen J. Lauer, Judith Ochs, Brad H. Pollock, George R. Buchanan

Institutions: Medical College of Wisconsin, Midwest Athletes Against Childhood Cancer, Inc., St. Jude Children's Research Hospital, University of Florida, The University of Texas Southwestern Medical Center

Language: English

Topic: Acute Lymphoblastic Leukemia research

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Midwest Athletes Against Childhood Cancer, National Institutes of Health, National Cancer Institute